Search results
Results from the WOW.Com Content Network
The last reason to buy this stock today is that its balance sheet is looking as good as it gets in biotech. At the end of the first quarter, it had around $2.1 billion in cash, cash equivalents ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why.
For premium support please call: 800-290-4726 more ways to reach us
Science & Tech. Shopping. Sports